|
1
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS
oncogenes and mismatch-repair status. Nature. 418:9342002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Normanno N, Maiello MR and De Luca A:
Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs): Simple drugs with a complex mechanism of action? J
Cell Physiol. 194:13–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tol J, Nagtegaal ID and Punt CJA: BRAF
mutation in metastatic colorectal cancer. N Engl J Med. 361:98–99.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kadowaki S, Kakuta M, Takahashi S,
Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K,
Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in
curatively resected colorectal cancer. World J Gastroenterol.
21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kopetz S, Desai J, Chan E, Hecht JR,
O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, et al:
Phase II pilot study of vemurafenib in patients with metastatic
BRAF-mutated colorectal cancer. J Clin Oncol. 33:4032–4038. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: Updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loupakis F, Cremolini C, Salvatore L, Masi
G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi
C, et al: FOLFOXIRI plus bevacizumab as first-line treatment in
BRAF mutant metastatic colorectal cancer. Eur J Cancer. 50:57–63.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Corcoran RB, Atreya CE, Falchook GS, Kwak
EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock
R, et al: Combined BRAF and MEK inhibition with dabrafenib and
trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol.
33:4023–4031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda Guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klein CA: Parallel progression of primary
tumours and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forrester K, Almoguera C, Han K, Grizzle
WE and Perucho M: Detection of high incidence of K-ras oncogenes
during human colon tumorigenesis. Nature. 327:298–303. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paliogiannis P, Cossu A, Tanda F, Palmieri
G and Palomba G: KRAS mutational concordance between primary and
metastatic colorectal adenocarcinoma. Oncol Lett. 8:1422–1426.
2014.PubMed/NCBI
|
|
23
|
Miglio U, Mezzapelle R, Paganotti A,
Allegrini S, Veggiani C, Antona J, Gentilli S, Monga G, Alabiso O
and Boldorini R: Mutation analysis of KRAS in primary colorectal
cancer and matched metastases by means of highly sensitivity
molecular assay. Pathol Res Pract. 209:233–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vakiani E, Janakiraman M, Shen R, Sinha R,
Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al:
Comparative genomic analysis of primary versus metastatic
colorectal carcinomas. J Clin Oncol. 30:2956–2962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akagi K, Uchibori R, Yamaguchi K, Kurosawa
K, Tanaka Y and Kozu T: Characterization of a novel oncogenic K-ras
mutation in colon cancer. Biochem Biophys Res Commun. 352:728–732.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogura T, Kakuta M, Yatsuoka T, Nishimura
Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y and Akagi K:
Clinicopathological characteristics and prognostic impact of
colorectal cancers with NRAS mutations. Oncol Rep. 32:50–56.
2014.PubMed/NCBI
|
|
27
|
Asaka S, Arai Y, Nishimura Y, Yamaguchi K,
Ishikubo T, Yatsuoka T, Tanaka Y and Akagi K: Microsatellite
instability-low colorectal cancer acquires a KRAS mutation during
the progression from Dukes' A to Dukes' B. Carcinogenesis.
30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mao C, Wu XY, Yang ZY, Threapleton DE,
Yuan JQ, Yu YY and Tang JL: Concordant analysis of KRAS, BRAF,
PIK3CA mutations, and PTEN expression between primary colorectal
cancer and matched metastases. Sci Rep. 5:80652015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knijn N, Mekenkamp LJ, Klomp M,
Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma
S, van Krieken JH, et al: KRAS mutation analysis: A comparison
between primary tumours and matched liver metastases in 305
colorectal cancer patients. Br J Cancer. 104:1020–1026. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haraldsdottir S, Roth R, Pearlman R,
Hampel H, Arnold CA and Frankel WL: Mismatch repair deficiency
concordance between primary colorectal cancer and corresponding
metastasis. Fam Cancer. 15:253–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baisse B, Bouzourene H, Saraga EP, Bosman
FT and Benhattar J: Intratumor genetic heterogeneity in advanced
human colorectal adenocarcinoma. Int J Cancer. 93:346–352. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Losi L, Baisse B, Bouzourene H and
Benhattar J: Evolution of intratumoral genetic heterogeneity during
colorectal cancer progression. Carcinogenesis. 26:916–922. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Molinari F, Martin V, Saletti P, De Dosso
S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and
Frattini M: Differing deregulation of EGFR and downstream proteins
in primary colorectal cancer and related metastatic sites may be
clinically relevant. Br J Cancer. 100:1087–1094. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uchi R, Takahashi Y, Niida A, Shimamura T,
Hirata H, Sugimachi K, Sawada G, Iwaya T, Kurashige J, Shinden Y,
et al: Integrated multiregional analysis proposing a new model of
colorectal cancer evolution. PLoS Genet. 12:e10057782016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gattenlöhner S, Etschmann B, Kunzmann V,
Thalheimer A, Hack M, Kleber G, Einsele H, Germer C and
Müller-Hermelink HK: Concordance of KRAS/BRAF mutation status in
metastatic colorectal cancer before and after anti-EGFR therapy. J
Oncol. 2009:8316262009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim M-J, Lee HS, Kim JH, Kim YJ, Kwon JH,
Lee J-O, Bang S-M, Park KU, Kim D-W, Kang S-B, et al: Different
metastatic pattern according to the KRAS mutational status and
site-specific discordance of KRAS status in patients with
colorectal cancer. BMC Cancer. 12:3472012. View Article : Google Scholar : PubMed/NCBI
|
